Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | CA9 | Q16790 | 2/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | PPARA | Q07869 | 3/20 | 0.37 |
| ▸ | PPARD | Q03181 | 2/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.37 |
| ▸ | ELANE | P08246 | 1/20 | 0.37 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.36 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.36 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA3 | P07451 | 1/20 | 0.35 |
| ▸ | CA6 | P23280 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL435736 | 0.79 | KIF11 (0.47) | KIF11ALDH1A1CYP2A6CA2CA9 | |
| SCHEMBL9626379 | 0.79 | CYP2A6 (0.40) | KIF11ALDH1A1CYP2A6CA2CA9 | |
| SCHEMBL9196159 | 0.78 | ACHE (0.41) | ALDH1A1CYP2A6CA2CA9CA1 | |
| SCHEMBL2008822 | 0.78 | ELANE (0.56) | ALDH1A1CA2CA9CA1MAPT | |
| SCHEMBL506442 | 0.77 | KIF11 (0.41) | KIF11ALDH1A1CYP2A6CA2CA9 | |
| SCHEMBL3843067 | 0.76 | ELANE (0.35) | ELANE | |
| SCHEMBL15241846 | 0.76 | CA2 (0.46) | KIF11ALDH1A1CYP2A6CA2CA9 | |
| SCHEMBL22649193 | 0.76 | MAOB (0.44) | KIF11ALDH1A1CYP2A6CA2CA9 | |
| SCHEMBL21408547 | 0.76 | MEN1 (0.48) | ALDH1A1ELANEKDM4EMEN1LMNA | |
| SCHEMBL9581834 | 0.76 | MAPT (0.44) | KIF11ALDH1A1CA2CA9CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-6219985-A | — | — | None | — | — | JP | disclosed |
| US-9718817-B2 | Aryl and heteroaryl ether compounds as ROR gamma modulators | GLENMARK PHARMACEUTICALS S.A. (CH) | 2017-08-01 | — | — | US | disclosed |
| US-9718817-B2 | Aryl and heteroaryl ether compounds as ROR gamma modulators | GLENMARK PHARMACEUTICALS S.A. (CH) | 2017-08-01 | — | — | US | disclosed |
| EP-3131880-A1 | ARYL AND HETEROARYL ETHER COMPOUNDS AS ROR GAMMA MODULATORS | Glenmark Pharmaceuticals S.A. (CH) | 2017-02-22 | — | — | EP | disclosed |
| US-20170022195-A1 | ARYL AND HETEROARYL ETHER COMPOUNDS AS ROR GAMMA MODULATORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2017-01-26 | — | — | US | disclosed |
| US-20170022195-A1 | ARYL AND HETEROARYL ETHER COMPOUNDS AS ROR GAMMA MODULATORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2017-01-26 | — | — | US | disclosed |
| WO-2015159233-A1 | ARYL AND HETEROARYL ETHER COMPOUNDS AS ROR GAMMA MODULATORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2015-10-22 | — | — | WO | disclosed |
| EP-1192170-B1 | PROPARGYL PHENYL ETHER A2A RECEPTOR AGONISTS | CV THERAPEUTICS INC (US) | 2003-05-14 | — | — | EP | disclosed |
| EP-1192170-A1 | PROPARGYL PHENYL ETHER A2A RECEPTOR AGONISTS | CV THERAPEUTICS, INC. (US) | 2002-04-03 | — | — | EP | disclosed |
| US-6180615-B1 | STIMULATE MAMMALIAN CORONARY VASODILATATION FOR THERAPEUTIC PURPOSES AND FOR PURPOSES OF IMAGING THE HEART | CV THERAPEUTICS, INC. | 2001-01-30 | — | — | US | disclosed |
| WO-2000078777-A1 | PROPARGYL PHENYL ETHER A2A RECEPTOR AGONISTS | CV THERAPEUTICS, INC. (US) | 2000-12-28 | — | — | WO | disclosed |
| US-5536833-A | Process for the preparation of intermediates useful in the preparation of pyranyl cyanoguanidine derivatives | E. R. SQUIBB & SONS, INC. (US) | 1996-07-16 | — | — | US | disclosed |
| US-5463059-A | Process for the preparation of intermediates useful in the preparation of pyranyl cyanoguanidine derivatives | E. R. SQUIBB & SONS, INC. (US) | 1995-10-31 | — | — | US | disclosed |
| JP-H06219985-A | PREPARATION OF INTERMEDIATE USEFUL IN PREPARATION OF PYRANYL CYANOGUANIDINE DERIVATIVE | E R SQUIBB & SONS INC | 1994-08-09 | — | — | JP | disclosed |
| EP-0600617-A1 | Process for the preparation of intermediates useful in the preparation of pyranyl cyanoguanidine derivatives | E.R. SQUIBB & SONS, INC. (US) | 1994-06-08 | — | — | EP | disclosed |
| US-5118694-A | Hypotensive agents; treatment for cardiovascular and muscular disorders | HOFFMANN-LA ROCHE INC. (US) | 1992-06-02 | — | — | US | disclosed |
| US-4971982-A | HYPOTENSIVE AGENTS, CARDIOVASCULAR DISORDERS, SMOOTH MUSCLE DISORDERS | HOFFMANN-LA ROCHE INC. (US) | 1990-11-20 | — | — | US | disclosed |
| US-4758677-A | Cyanobenzano [b] pyrans | BEECHAM GROUP P.L.C (GB) | 1988-07-19 | — | — | US | disclosed |
| US-4391815-A | VASODILATION, HYPOTENSIVE | BEECHAM GROUP LIMITED (GB) | 1983-07-05 | — | — | US | disclosed |
| US-4251537-A | Hypotensive 3,4-dihydro-2,2-dimethyl-4-amino-2H-benzo[b]pyran-3-ols | BEECHAM GROUP LIMITED (GB) | 1981-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170022195-A1 | ARYL AND HETEROARYL ETHER COMPOUNDS AS ROR GAMMA MODULATORS | RORB, RORA, RORC | KIF11 3777/4885ALDH1A1 1250/4885CYP2A6 319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.